Cargando…

Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes

In diabetes mellitus (DM) treatment, Continuous Glucose Monitoring (CGM) linked with insulin delivery becomes the main strategy to improve therapeutic outcomes and quality of patients’ lives. However, Blood Glucose (BG) regulation with CGM is still hampered by limitations of algorithms and glucose s...

Descripción completa

Detalles Bibliográficos
Autores principales: Olçomendy, Loïc, Cassany, Louis, Pirog, Antoine, Franco, Roberto, Puginier, Emilie, Jaffredo, Manon, Gucik-Derigny, David, Ríos, Héctor, Ferreira de Loza, Alejandra, Gaitan, Julien, Raoux, Matthieu, Bornat, Yannick, Catargi, Bogdan, Lang, Jochen, Henry, David, Renaud, Sylvie, Cieslak, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072637/
https://www.ncbi.nlm.nih.gov/pubmed/35528003
http://dx.doi.org/10.3389/fendo.2022.795225
_version_ 1784701103533719552
author Olçomendy, Loïc
Cassany, Louis
Pirog, Antoine
Franco, Roberto
Puginier, Emilie
Jaffredo, Manon
Gucik-Derigny, David
Ríos, Héctor
Ferreira de Loza, Alejandra
Gaitan, Julien
Raoux, Matthieu
Bornat, Yannick
Catargi, Bogdan
Lang, Jochen
Henry, David
Renaud, Sylvie
Cieslak, Jérôme
author_facet Olçomendy, Loïc
Cassany, Louis
Pirog, Antoine
Franco, Roberto
Puginier, Emilie
Jaffredo, Manon
Gucik-Derigny, David
Ríos, Héctor
Ferreira de Loza, Alejandra
Gaitan, Julien
Raoux, Matthieu
Bornat, Yannick
Catargi, Bogdan
Lang, Jochen
Henry, David
Renaud, Sylvie
Cieslak, Jérôme
author_sort Olçomendy, Loïc
collection PubMed
description In diabetes mellitus (DM) treatment, Continuous Glucose Monitoring (CGM) linked with insulin delivery becomes the main strategy to improve therapeutic outcomes and quality of patients’ lives. However, Blood Glucose (BG) regulation with CGM is still hampered by limitations of algorithms and glucose sensors. Regarding sensor technology, current electrochemical glucose sensors do not capture the full spectrum of other physiological signals, i.e., lipids, amino acids or hormones, relaying the general body status. Regarding algorithms, variability between and within patients remains the main challenge for optimal BG regulation in closed-loop therapies. This work highlights the simulation benefits to test new sensing and control paradigms which address the previous shortcomings for Type 1 Diabetes (T1D) closed-loop therapies. The UVA/Padova T1DM Simulator is the core element here, which is a computer model of the human metabolic system based on glucose-insulin dynamics in T1D patients. That simulator is approved by the US Food and Drug Administration (FDA) as an alternative for pre-clinical testing of new devices and closed-loop algorithms. To overcome the limitation of standard glucose sensors, the concept of an islet-based biosensor, which could integrate multiple physiological signals through electrical activity measurement, is assessed here in a closed-loop insulin therapy. This investigation has been addressed by an interdisciplinary consortium, from endocrinology to biology, electrophysiology, bio-electronics and control theory. In parallel to the development of an islet-based closed-loop, it also investigates the benefits of robust control theory against the natural variability within a patient population. Using 4 meal scenarios, numerous simulation campaigns were conducted. The analysis of their results then introduces a discussion on the potential benefits of an Artificial Pancreas (AP) system associating the islet-based biosensor with robust algorithms.
format Online
Article
Text
id pubmed-9072637
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90726372022-05-07 Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes Olçomendy, Loïc Cassany, Louis Pirog, Antoine Franco, Roberto Puginier, Emilie Jaffredo, Manon Gucik-Derigny, David Ríos, Héctor Ferreira de Loza, Alejandra Gaitan, Julien Raoux, Matthieu Bornat, Yannick Catargi, Bogdan Lang, Jochen Henry, David Renaud, Sylvie Cieslak, Jérôme Front Endocrinol (Lausanne) Endocrinology In diabetes mellitus (DM) treatment, Continuous Glucose Monitoring (CGM) linked with insulin delivery becomes the main strategy to improve therapeutic outcomes and quality of patients’ lives. However, Blood Glucose (BG) regulation with CGM is still hampered by limitations of algorithms and glucose sensors. Regarding sensor technology, current electrochemical glucose sensors do not capture the full spectrum of other physiological signals, i.e., lipids, amino acids or hormones, relaying the general body status. Regarding algorithms, variability between and within patients remains the main challenge for optimal BG regulation in closed-loop therapies. This work highlights the simulation benefits to test new sensing and control paradigms which address the previous shortcomings for Type 1 Diabetes (T1D) closed-loop therapies. The UVA/Padova T1DM Simulator is the core element here, which is a computer model of the human metabolic system based on glucose-insulin dynamics in T1D patients. That simulator is approved by the US Food and Drug Administration (FDA) as an alternative for pre-clinical testing of new devices and closed-loop algorithms. To overcome the limitation of standard glucose sensors, the concept of an islet-based biosensor, which could integrate multiple physiological signals through electrical activity measurement, is assessed here in a closed-loop insulin therapy. This investigation has been addressed by an interdisciplinary consortium, from endocrinology to biology, electrophysiology, bio-electronics and control theory. In parallel to the development of an islet-based closed-loop, it also investigates the benefits of robust control theory against the natural variability within a patient population. Using 4 meal scenarios, numerous simulation campaigns were conducted. The analysis of their results then introduces a discussion on the potential benefits of an Artificial Pancreas (AP) system associating the islet-based biosensor with robust algorithms. Frontiers Media S.A. 2022-04-22 /pmc/articles/PMC9072637/ /pubmed/35528003 http://dx.doi.org/10.3389/fendo.2022.795225 Text en Copyright © 2022 Olçomendy, Cassany, Pirog, Franco, Puginier, Jaffredo, Gucik-Derigny, Ríos, Ferreira de Loza, Gaitan, Raoux, Bornat, Catargi, Lang, Henry, Renaud and Cieslak https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Olçomendy, Loïc
Cassany, Louis
Pirog, Antoine
Franco, Roberto
Puginier, Emilie
Jaffredo, Manon
Gucik-Derigny, David
Ríos, Héctor
Ferreira de Loza, Alejandra
Gaitan, Julien
Raoux, Matthieu
Bornat, Yannick
Catargi, Bogdan
Lang, Jochen
Henry, David
Renaud, Sylvie
Cieslak, Jérôme
Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
title Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
title_full Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
title_fullStr Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
title_full_unstemmed Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
title_short Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
title_sort towards the integration of an islet-based biosensor in closed-loop therapies for patients with type 1 diabetes
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072637/
https://www.ncbi.nlm.nih.gov/pubmed/35528003
http://dx.doi.org/10.3389/fendo.2022.795225
work_keys_str_mv AT olcomendyloic towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT cassanylouis towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT pirogantoine towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT francoroberto towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT puginieremilie towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT jaffredomanon towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT gucikderignydavid towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT rioshector towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT ferreiradelozaalejandra towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT gaitanjulien towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT raouxmatthieu towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT bornatyannick towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT catargibogdan towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT langjochen towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT henrydavid towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT renaudsylvie towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes
AT cieslakjerome towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes